PHARMACYTE BIOTECH, INC. (PMCB) Scorecard
- 2026-Q2: Total return Win; Revenue growth No data; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth No data; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth No data; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth No data; EPS growth Lose.
13/53
1.2 / 5 stars
All 53 Win/Lose results and 67 gray no-data contests shown below
Every strict quarterly win earns 1 point. A loss or tie earns 0. A contest with no data is a gray cell, neither a win nor a loss, and leaves the total: stars are 5 × points won ÷ contests with data.
Trailing 1 year (4 quarters): 1 wins, 7 losses, 4 no dataLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/2 |
WinPMCB / S&P 15.72% / 15.20% |
No dataPMCB / S&P / 15.00% |
LosePMCB / S&P -215.83% / 50.40% |
| 2026-Q10/2 |
LosePMCB / S&P -8.09% / -4.33% |
No dataPMCB / S&P / 11.30% |
LosePMCB / S&P -251.35% / 27.70% |
| 2025-Q40/2 |
LosePMCB / S&P -25.33% / 2.65% |
No dataPMCB / S&P / 9.00% |
LosePMCB / S&P -362.26% / 13.40% |
| 2025-Q30/2 |
LosePMCB / S&P -11.05% / 8.12% |
No dataPMCB / S&P / 4.61% |
LosePMCB / S&P -181.82% / 13.45% |
| 2025-Q20/2 |
LosePMCB / S&P -12.80% / 10.94% |
No dataPMCB / S&P / 4.83% |
LosePMCB / S&P -245.51% / 10.63% |
| 2025-Q10/2 |
LosePMCB / S&P -20.38% / -4.27% |
No dataPMCB / S&P / 4.98% |
LosePMCB / S&P -150.68% / 10.57% |
| 2024-Q40/2 |
LosePMCB / S&P -17.80% / 2.41% |
No dataPMCB / S&P / 5.25% |
LosePMCB / S&P -162.35% / 6.15% |
| 2024-Q30/2 |
LosePMCB / S&P -2.55% / 5.89% |
No dataPMCB / S&P / 5.89% |
LosePMCB / S&P -197.06% / 6.11% |
| 2024-Q21/2 |
LosePMCB / S&P -17.30% / 4.28% |
No dataPMCB / S&P / 5.38% |
WinPMCB / S&P 747.62% / 5.12% |
| 2024-Q11/2 |
LosePMCB / S&P 9.72% / 10.56% |
No dataPMCB / S&P / 5.71% |
WinPMCB / S&P 461.54% / 5.59% |
| 2023-Q41/2 |
LosePMCB / S&P 2.86% / 11.69% |
No dataPMCB / S&P / 6.81% |
WinPMCB / S&P 226.92% / 7.78% |
| 2023-Q31/2 |
LosePMCB / S&P -26.57% / -3.27% |
No dataPMCB / S&P / 7.52% |
WinPMCB / S&P 195.65% / -5.03% |
| 2023-Q20/2 |
LosePMCB / S&P -1.72% / 8.74% |
No dataPMCB / S&P / 9.50% |
LosePMCB / S&P -73.75% / -8.57% |
| 2023-Q10/1 |
LosePMCB / S&P -0.68% / 7.50% |
No dataPMCB / S&P / 10.77% |
No dataPMCB / S&P / -15.69% |
| 2022-Q41/1 |
WinPMCB / S&P 22.08% / 7.56% |
No dataPMCB / S&P / 11.88% |
No dataPMCB / S&P / -17.99% |
| 2022-Q31/1 |
WinPMCB / S&P 7.14% / -4.88% |
No dataPMCB / S&P / 13.47% |
No dataPMCB / S&P / -1.41% |
| 2022-Q21/1 |
WinPMCB / S&P -2.61% / -16.10% |
No dataPMCB / S&P / 13.71% |
No dataPMCB / S&P / 11.04% |
| 2022-Q10/1 |
LosePMCB / S&P -8.00% / -4.60% |
No dataPMCB / S&P / 15.97% |
No dataPMCB / S&P / 42.23% |
| 2021-Q40/1 |
LosePMCB / S&P -21.14% / 11.03% |
No dataPMCB / S&P / 15.00% |
No dataPMCB / S&P / 96.40% |
| 2021-Q30/1 |
LosePMCB / S&P -81.06% / 0.58% |
No dataPMCB / S&P / 10.77% |
No dataPMCB / S&P / 69.42% |
| 2021-Q20/1 |
LosePMCB / S&P -36.84% / 8.55% |
No dataPMCB / S&P / 6.58% |
No dataPMCB / S&P / 51.81% |
| 2021-Q11/1 |
WinPMCB / S&P 155.22% / 6.17% |
No dataPMCB / S&P / -1.06% |
No dataPMCB / S&P / 7.39% |
| 2020-Q40/1 |
LosePMCB / S&P -60.59% / 12.15% |
No dataPMCB / S&P / -3.72% |
No dataPMCB / S&P / -33.42% |
| 2020-Q30/1 |
LosePMCB / S&P -33.85% / 8.93% |
No dataPMCB / S&P / -2.04% |
No dataPMCB / S&P / -27.10% |
| 2020-Q20/1 |
LosePMCB / S&P -14.33% / 20.54% |
No dataPMCB / S&P / -0.46% |
No dataPMCB / S&P / -27.11% |
| 2020-Q10/1 |
LosePMCB / S&P -25.93% / -19.60% |
No dataPMCB / S&P / 3.47% |
No dataPMCB / S&P / -14.75% |
| 2019-Q41/1 |
WinPMCB / S&P 10.05% / 9.07% |
No dataPMCB / S&P / 5.36% |
No dataPMCB / S&P / 2.99% |
| 2019-Q30/1 |
LosePMCB / S&P -5.64% / 1.70% |
No dataPMCB / S&P / 5.02% |
No dataPMCB / S&P / 0.21% |
| 2019-Q20/1 |
LosePMCB / S&P -19.75% / 4.30% |
No dataPMCB / S&P / 6.64% |
No dataPMCB / S&P / 8.65% |
| 2019-Q11/1 |
WinPMCB / S&P 31.35% / 13.65% |
No dataPMCB / S&P / 8.12% |
No dataPMCB / S&P / 14.29% |
| 2018-Q40/1 |
LosePMCB / S&P -35.31% / -13.52% |
No dataPMCB / S&P / 9.05% |
No dataPMCB / S&P / 18.23% |
| 2018-Q30/1 |
LosePMCB / S&P -16.25% / 7.71% |
No dataPMCB / S&P / 10.21% |
No dataPMCB / S&P / 19.06% |
| 2018-Q21/1 |
WinPMCB / S&P 29.36% / 3.43% |
No dataPMCB / S&P / 9.03% |
No dataPMCB / S&P / 14.46% |
| 2018-Q10/1 |
LosePMCB / S&P -5.38% / -0.76% |
No dataPMCB / S&P / 7.68% |
No dataPMCB / S&P / 12.46% |
| 2017-Q40/1 |
LosePMCB / S&P -3.79% / 6.64% |
No dataPMCB / S&P / 7.03% |
No dataPMCB / S&P / 13.82% |
| 2017-Q30/1 |
LosePMCB / S&P 3.39% / 4.48% |
No dataPMCB / S&P / 5.68% |
No dataPMCB / S&P / 17.57% |
| 2017-Q20/1 |
LosePMCB / S&P -43.05% / 3.09% |
No dataPMCB / S&P / 4.83% |
No dataPMCB / S&P / 17.74% |
| 2017-Q10/1 |
LosePMCB / S&P -33.85% / 6.07% |
No dataPMCB / S&P / 3.67% |
No dataPMCB / S&P / 13.32% |
| 2016-Q41/1 |
WinPMCB / S&P 325.43% / 3.82% |
No dataPMCB / S&P / 2.09% |
No dataPMCB / S&P / 7.05% |
| 2016-Q30/1 |
LosePMCB / S&P -36.01% / 3.85% |
No dataPMCB / S&P / 0.20% |
No dataPMCB / S&P / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | PMCB total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -42.47% | 20.78% |
| Annualized return | -42.47% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | PMCB total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -84.34% | 83.14% |
| Annualized return | -30.98% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | PMCB total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.02% | 319.30% |
| Annualized return | -37.00% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |